How are energy investors positioned?
Investing.com - H.C. Wainwright has reiterated its Buy rating and $12.00 price target on TuHURA Biosciences (NASDAQ:HURA) following the company’s second-quarter financial results. The price target represents significant upside from the current trading price of $2.91, though InvestingPro analysis suggests the stock may be overvalued at current levels.
TuHURA reported a net loss of $0.21 per share for the second quarter of 2025, which was wider than H.C. Wainwright’s previous estimate of a $0.14 per share loss.
The company’s research and development expenses reached $4.93 million while selling, general, and administrative expenses totaled $4.95 million, compared to the research firm’s estimates of $4.7 million and $2.5 million, respectively.
H.C. Wainwright has updated its projections for TuHURA, now forecasting a full-year 2025 net loss of $0.66 per share.
TuHURA ended the second quarter with approximately $8.5 million in cash, cash equivalents, and marketable securities, with H.C. Wainwright anticipating an additional equity raise of roughly $20 million in the fourth quarter of 2025.
In other recent news, TuHURA Biosciences has completed the acquisition of Kineta, adding a Phase 2 ready VISTA inhibiting monoclonal antibody to its pipeline. This acquisition follows the approval of all merger-related proposals by stockholders from both companies. In addition, TuHURA has initiated a Phase 3 trial for its lead drug candidate, IFx-2.0, in patients with advanced or metastatic Merkel cell carcinoma. The trial is being conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration. H.C. Wainwright has reiterated its Buy rating on TuHURA Biosciences, maintaining a price target of $12.00. The company has also been added to the Russell 3000 and 2000 indexes, marking a significant milestone in its first year as a publicly traded entity. These developments highlight TuHURA’s ongoing efforts in expanding its cancer immunotherapy portfolio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.